ME Therapeutics Holdings Inc.
METX
CNSX
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.44% | 55.85% | |||
| Depreciation & Amortization | 6.01% | 27.97% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.04% | 79.25% | |||
| Operating Income | -14.04% | -79.25% | |||
| Income Before Tax | 1.87% | -79.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.87% | -79.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.87% | -79.96% | |||
| EBIT | -14.04% | -79.25% | |||
| EBITDA | -14.18% | -79.02% | |||
| EPS Basic | 2.35% | -63.46% | |||
| Normalized Basic EPS | 1.89% | -60.61% | |||
| EPS Diluted | 2.35% | -21.43% | |||
| Normalized Diluted EPS | 1.89% | -60.61% | |||
| Average Basic Shares Outstanding | 0.07% | 10.27% | |||
| Average Diluted Shares Outstanding | 0.07% | 10.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||